AbbVie Shares Dip Amid Market Volatility

Analysts Weigh In on Pharmaceutical Giant's Performance

Apr. 1, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

Shares of AbbVie Inc. (NYSE:ABBV) fell 1.3% during trading on Wednesday, closing at $214.72. The decline came amid broader market volatility, with approximately 5.6 million shares traded, down 24% from the average daily volume. The pharmaceutical company's stock has seen mixed analyst sentiment in recent weeks.

Why it matters

As a major player in the pharmaceutical industry, AbbVie's stock performance is closely watched by investors and analysts. The company's diverse product portfolio and pipeline of new therapies make it an important barometer for the broader healthcare sector.

The details

Several research firms have recently weighed in on AbbVie, with Evercore lowering its price target to $228 from $232 and maintaining an "outperform" rating. Meanwhile, Wall Street Zen upgraded the stock to a "strong-buy" rating, and BMO Capital Markets reiterated an "outperform" rating. The Goldman Sachs Group reaffirmed a "neutral" rating and $223 price target.

  • Shares of AbbVie traded as low as $213.75 on Wednesday.
  • The stock closed at $217.49 on the previous trading day.

The players

AbbVie Inc.

A global, research-driven biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions.

Evercore

An investment banking advisory firm that recently lowered its price target on AbbVie shares.

Wall Street Zen

A financial research firm that upgraded AbbVie's rating to "strong-buy".

BMO Capital Markets

An investment bank that reiterated an "outperform" rating on AbbVie's stock.

The Goldman Sachs Group

A leading global investment banking and securities firm that reaffirmed a "neutral" rating on AbbVie.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain cautious on AbbVie's near-term performance amid broader market volatility.”

— Analyst

“AbbVie's diverse portfolio and pipeline of new therapies make it a strong long-term investment.”

— Analyst

What’s next

Investors will be closely watching AbbVie's upcoming earnings report and any updates on its pipeline of new drug candidates.

The takeaway

AbbVie's stock performance reflects the broader volatility in the pharmaceutical sector, but the company's strong product portfolio and research pipeline continue to make it an attractive long-term investment for many analysts.